Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.14

-2.0%

10:35 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (183)	4/22/1999 10:20:00 PM
From: LLCF	Read Replies (1) of 52153

Insiders piling into one of our "value" stocks: Guilford Pharmaceuticals (Nasdaq: GLFD) $10.00. This biopharmaceutical company that specializes in drug delivery systems of the treatment of cancer trades at roughly 1.4 times book value, and 1.6 times cash. The stock also trades near its 12-month low. Despite a lack of earnings in the foreseeable future, insiders appear enthused. Execs bought 58,000 shares at an average price of $10.28 per share in March. Estimates are calling for the company to lose $1.22 per share and $1.21 per share in FY 1999 and FY 2000 respectively. DAK

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next